• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

头颈部癌的再程放疗：长期疾病控制与毒性反应

Reirradiation of head and neck cancer: Long-term disease control and toxicity.

作者信息

Bots Wouter T C, van den Bosch Sven, Zwijnenburg Ellen M, Dijkema Tim, van den Broek Guido B, Weijs Willem L J, Verhoef Lia C G, Kaanders Johannes H A M

机构信息

Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.

Department of Otorhinolaryngology Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Head Neck. 2017 Jun;39(6):1122-1130. doi: 10.1002/hed.24733. Epub 2017 Mar 6.

DOI:10.1002/hed.24733
PMID:28263446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5485062/
Abstract

BACKGROUND

The purpose of this study was to report long-term disease control and late radiation toxicity for patients reirradiated for head and neck cancer.

METHODS

We conducted a retrospective analysis of 137 patients reirradiated with a prescribed dose ≥45 Gy between 1986 and 2013 for a recurrent or second primary malignancy. Endpoints were locoregional control, overall survival (OS), and grade ≥4 late complications according to European Organization for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) criteria.

RESULTS

Five-year locoregional control rates were 46% for patients reirradiated postoperatively versus 20% for patients who underwent reirradiation as the primary treatment (p < .05). Sixteen cases of serious (grade ≥4) late toxicity were seen in 11 patients (actuarial 28% at 5 years). In patients reirradiated with intensity-modulated radiotherapy (IMRT), a borderline improved locoregional control was observed (49% vs 36%; p = .07), whereas late complication rates did not differ.

CONCLUSION

Reirradiation should be considered for patients with a recurrent or second primary head and neck cancer, especially postoperatively, if indicated. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1122-1130, 2017.

摘要

背景

本研究旨在报告接受头颈部癌再程放疗患者的长期疾病控制情况及晚期放射毒性。

方法

我们对1986年至2013年间因复发性或第二原发性恶性肿瘤接受≥45 Gy处方剂量再程放疗的137例患者进行了回顾性分析。终点指标为局部区域控制、总生存期（OS）以及根据欧洲癌症研究与治疗组织（EORTC）/放射肿瘤学组（RTOG）标准判定的≥4级晚期并发症。

结果

术后接受再程放疗患者的5年局部区域控制率为46%，而接受再程放疗作为初始治疗的患者为20%（p <.05）。11例患者出现16例严重（≥4级）晚期毒性反应（5年精算发生率为28%）。在接受调强放疗（IMRT）再程放疗的患者中，观察到局部区域控制有边际性改善（49%对36%；p = 0.07），而晚期并发症发生率无差异。

结论

对于复发性或第二原发性头颈部癌患者，尤其是术后患者，若有指征，应考虑再程放疗。© 2017威利期刊公司。《头颈》39: 1122 - 1130, 2017。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/ae822f7844d8/HED-39-1122-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/53cdaf7e1816/HED-39-1122-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/87b20834716b/HED-39-1122-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/8a4d8137115f/HED-39-1122-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/ae822f7844d8/HED-39-1122-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/53cdaf7e1816/HED-39-1122-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/87b20834716b/HED-39-1122-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/8a4d8137115f/HED-39-1122-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a9f/5485062/ae822f7844d8/HED-39-1122-g004.jpg

相似文献

1
Reirradiation of head and neck cancer: Long-term disease control and toxicity.头颈部癌的再程放疗：长期疾病控制与毒性反应
Head Neck. 2017 Jun;39(6):1122-1130. doi: 10.1002/hed.24733. Epub 2017 Mar 6.
2
Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.基于调强放疗的头颈部癌症再放疗的容积、剂量和分割考虑因素：多机构分析。
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):606-617. doi: 10.1016/j.ijrobp.2017.11.036. Epub 2017 Dec 1.
3
Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma.调强放疗用于局部复发性T3至T4期鼻咽癌的再程放疗。
Head Neck. 2017 Mar;39(3):533-540. doi: 10.1002/hed.24645. Epub 2016 Nov 29.
4
High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity.大剂量调强放疗治疗复发性头颈部肿瘤：疾病控制、生存和毒性。
Radiother Oncol. 2014 Jun;111(3):388-92. doi: 10.1016/j.radonc.2014.04.018. Epub 2014 Jul 3.
5
Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.在调强放疗时代对头颈部鳞癌进行再放疗的患者选择的优化：MIRI 协作的多机构队列研究。
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):586-594. doi: 10.1016/j.ijrobp.2017.06.012. Epub 2017 Jun 17.
6
IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.头颈部癌的调强适形放疗再程照射——疾病控制及并发症结果
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):399-409. doi: 10.1016/j.ijrobp.2008.04.021. Epub 2008 Jun 14.
7
Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707).基于调强放疗的头颈癌再程放疗：韩国放射肿瘤学组多机构研究（KROG 1707）
Cancer Res Treat. 2020 Oct;52(4):1031-1040. doi: 10.4143/crt.2020.310. Epub 2020 Jul 7.
8
A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.多机构比较 SBRT 和 IMRT 用于复发性或第二原发头颈部癌症的根治性再放疗。
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):595-605. doi: 10.1016/j.ijrobp.2017.04.017. Epub 2017 Apr 24.
9
Re-irradiation Using Intensity-modulated Radiotherapy for Recurrent and Second Primary Head and Neck Cancer.调强放射治疗用于复发性和第二原发性头颈癌的再程放疗
Anticancer Res. 2018 May;38(5):3165-3173. doi: 10.21873/anticanres.12580.
10
Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.复发性头颈癌的质子束再照射：多机构可行性及早期结果报告。
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):386-395. doi: 10.1016/j.ijrobp.2016.02.036. Epub 2016 Feb 17.

引用本文的文献

1
Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma.口咽癌和下咽癌基于证据的诊断、治疗、预防及术后护理指南
Ger Med Sci. 2025 Jun 24;23:Doc03. doi: 10.3205/000339. eCollection 2025.
2
'Line' Constraints Optimization for Improved Dose Distribution in Locally Recurrent Nasopharyngeal Carcinoma Using Knowledge-Based Planning.基于知识的计划中“线”约束优化以改善局部复发性鼻咽癌的剂量分布
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251351535. doi: 10.1177/15330338251351535. Epub 2025 Jun 18.
3
Interprofessional Team-Based Whole-Course Enteral Nutrition in the Peri-Radiation Therapy Period for Esophageal Cancer.

本文引用的文献

1
Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial.粒子治疗对头颈部患者再程放疗的益处。一项多中心计算机模拟ROCOCO试验的结果。
Radiother Oncol. 2016 Dec;121(3):387-394. doi: 10.1016/j.radonc.2016.08.020. Epub 2016 Sep 14.
2
Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.头颈部癌调强放射治疗再程放疗：结果与分析
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1117-31. doi: 10.1016/j.ijrobp.2016.03.015. Epub 2016 Mar 19.
3
Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic.
食管癌放疗围疗期基于跨专业团队的全疗程肠内营养
Clin J Oncol Nurs. 2025 May 19;29(3):E88-E96. doi: 10.1188/25.CJON.E88-E96.
4
A comparative dose-escalation analysis for reirradiated cancer patients with and without appropriate dose mapping.对接受再照射的癌症患者进行的有或没有适当剂量映射的比较剂量递增分析。
Radiat Environ Biophys. 2024 Mar;63(1):71-80. doi: 10.1007/s00411-023-01050-3. Epub 2023 Dec 11.
5
Advancements of radiotherapy for recurrent head and neck cancer in modern era.现代时代复发性头颈部癌症放射治疗的进展。
Radiat Oncol. 2023 Oct 6;18(1):166. doi: 10.1186/s13014-023-02342-0.
6
Reirradiation of head and neck squamous cell carcinomas: a pragmatic approach-part I: prognostic factors and indications to treatment.头颈部鳞癌的再放疗：实用方法-第 1 部分：预后因素和治疗指征。
Radiol Med. 2024 Jan;129(1):160-173. doi: 10.1007/s11547-023-01713-7. Epub 2023 Sep 20.
7
An Overview of Head and Neck Tumor Reirradiation: What Has Been Achieved So Far?头颈部肿瘤再程放疗概述：目前已取得哪些成果？
Cancers (Basel). 2023 Sep 4;15(17):4409. doi: 10.3390/cancers15174409.
8
Re-irradiation for head and neck cancer: outcome and toxicity analysis using a prospective single institution database.头颈部癌的再程放疗：使用前瞻性单机构数据库进行的疗效和毒性分析
Front Oncol. 2023 Jun 29;13:1175609. doi: 10.3389/fonc.2023.1175609. eCollection 2023.
9
Boron Neutron Capture Therapy Followed by Image-Guided Intensity-Modulated Radiotherapy for Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial.硼中子俘获疗法联合图像引导调强放射治疗局部复发性头颈癌：一项前瞻性I/II期试验
Cancers (Basel). 2023 May 15;15(10):2762. doi: 10.3390/cancers15102762.
10
Predictors of toxicity after curative reirradiation with intensity modulated radiotherapy or proton therapy for recurrent head and neck carcinoma: new dose constraints for pharyngeal constrictors muscles and oral cavity.调强放疗或质子治疗复发性头颈癌根治性再照射后毒性的预测因素：咽缩肌和口腔的新剂量限制
Strahlenther Onkol. 2023 Oct;199(10):901-909. doi: 10.1007/s00066-023-02080-y. Epub 2023 May 31.
梅奥诊所对具有治愈性意图进行再照射治疗的头颈部局部区域复发性或新发原发性鳞状细胞癌患者的治疗结果。
Radiat Oncol. 2016 Apr 9;11:55. doi: 10.1186/s13014-016-0630-x.
4
Reirradiation for second primary or recurrent cancers of the head and neck: Dosimetric and outcome analysis.头颈部第二原发性或复发性癌症的再程放疗：剂量学与疗效分析。
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E961-9. doi: 10.1002/hed.24136. Epub 2015 Aug 11.
5
High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity.大剂量调强放疗治疗复发性头颈部肿瘤：疾病控制、生存和毒性。
Radiother Oncol. 2014 Jun;111(3):388-92. doi: 10.1016/j.radonc.2014.04.018. Epub 2014 Jul 3.
6
Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.头颈部复发性和第二原发性鳞状细胞癌：何时以及如何再次放疗。
Head Neck. 2015 Jan;37(1):134-50. doi: 10.1002/hed.23542. Epub 2014 Jan 31.
7
Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.随机 III 期试验（GORTEC 98-03）比较了再放疗加化疗与甲氨蝶呤在姑息性治疗的复发性或第二原发头颈部鳞状细胞癌患者中的疗效。
Radiother Oncol. 2011 Jul;100(1):70-5. doi: 10.1016/j.radonc.2011.06.025. Epub 2011 Jul 7.
8
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.头颈部癌症化疗的荟萃分析（MACH-NC）：按肿瘤部位进行的综合分析。
Radiother Oncol. 2011 Jul;100(1):33-40. doi: 10.1016/j.radonc.2011.05.036. Epub 2011 Jun 16.
9
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.先前的放化疗会对接受同期化疗和再放疗的复发性和第二原发头颈部癌症的治疗结果产生不利影响。
Cancer. 2011 Oct 15;117(20):4671-8. doi: 10.1002/cncr.26084. Epub 2011 Jun 13.
10
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.ACR 适宜性标准：头颈部癌症根治性放疗后复发的再治疗 放射肿瘤学-头颈部癌症专家组
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1292-8. doi: 10.1016/j.ijrobp.2011.02.014. Epub 2011 Apr 27.